Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.
In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.
In March 2023, national telehealth utilization rose 1.8%, up from 5.5% of medical claim lines in February, according to new data from FAIR Health’s Monthly Telehealth Regional Tracker.
In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.
Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Although older patients generally accept electronic visits (e-visits) conducted via asynchronous messages, nearly two-thirds said they prefer visit types with synchronous dialogue.
Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.
With Medicare-aged Americans accounting for over 15% of the population and significant health care costs, stakeholders have leveraged various approaches, including the Medicare Current Beneficiary Survey, for estimating costs.
The decreasing cost of DNA sequencing has contributed to an uptick in genomic sequencing for precision diagnostics in rare diseases.
The new classifications included several major changes and may help identify different subtypes.
"It's really important that oncologists are on level footing along with the rest of their medical peers," said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.
It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time
Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Results are based on a study of low-dose interleukin-2 (IL-2) carried out at Dana-Farber Cancer Institute.
To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations.
Abstracts presented at EULAR 2023 highlighted the impact that a mandatory switching policy had on biosimilar uptake in British Columbia, Canada, and the lack of uptake when no such policy was in place in the United States.
Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham, talks about a new trial in which dupilumab was used in patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations and type 2 inflammation.
The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer.
Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics.
Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.
According to new estimates, the US government spent between $143 million and $314 million in 2022 inflation-adjusted dollars funding the development of tenofovir disoproxil fumarate-emtricitabine. The previous estimate was around $50 million.
Amal Agarwal, DO, MBA, chief clinical officer at Monogram Health, explains the importance of value-based agreements in dialysis care, and the issue of dialysis prevalence among low-income and marginalized communities.
The prevalence of high metabolism scores for visceral fat, especially among sensitive populations, may be associated with a heightened asthma risk, according to one study.
The study, wrote the researchers, offers insight into emerging and uncommon complications following chimeric antigen receptor (CAR) T-cell therapy.
Higher enablement was associated with being more comfortable to reconsult about persistent or worsening symptoms.
President Joe Biden has reportedly picked former North Carolina health chief Mandy Cohen, MD, MPH, as next head of the CDC; Black men were probably underdiagnosed with lung problems because of software bias; the US birthrate remains flat.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.
Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
